New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, NY, USA Abstract: The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies....
Enregistré dans:
Auteurs principaux: | Seetharamu N, Preeshagul IR, Sullivan KM |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8a0a5dfc63c14e2b808511bcd61aa5dd |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
par: Wolfram Samlowski, et autres
Publié: (2021) -
The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
par: Nikolai A. Ognerubov, et autres
Publié: (2021) -
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
par: Zoe Apalla, et autres
Publié: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
par: Anwen Xiong, et autres
Publié: (2021) -
Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
par: Galina B. Statsenko, et autres
Publié: (2020)